Biblio

Author Title [ Type

] Year

Filters: Author is Garnier, Alice [Clear All Filters]

Journal Article

Guillaume T, Dehame V, Chevallier P, Peterlin P, Garnier A, Gregoire M, Pichinuk E, Rubinstein DB, Wreschner DH. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Exp Hematol. 2018.

Guillaume T, Thépot S, Peterlin P, Ceballos P, Le Bourgeois A, Garnier A, Orvain C, Giltat A, François S, Le Bris Y, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome. Transplant Cell Ther. 2021.

Le Bourgeois A, Jullien M, Garnier A, Peterlin P, Béné MC, Guillaume T, Chevallier P. Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant. Clin Transl Med. 2023;13(4):e1242.

Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, et al. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. Am J Hematol. 2024.

Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, et al. Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies. Biol Blood Marrow Transplant. 2019.

Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. Cancer Med. 2021.

Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert B-M, Daguindau E, Mahe B, Dubruille V, Blin N, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Chérel M, Debord C, Le Bris Y, Theisen O, et al. FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine. 2019;120:85-87.

Chevallier P, Jullien M, Peterlin P, Garnier A, Le Bourgeois A, Coste-Burel M, Béné MC, Guillaume T. Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients. Hematol Oncol. 2022.

Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Early Post-Transplant Serum Ferritin Levels Predict Survivals in Recipients of Haploidentical Stem Cell Transplantation Using PTCY as GVHD Prophylaxis. Transplant Cell Ther. 2021.

Jullien M, Le Bourgeois A, Coste-Burel M, Peterlin P, Garnier A, Rimbert M, Imbert B-M, Le Gouill S, Moreau P, Mahe B, et al. B-cell aplasia is the most powerful predictive marker for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccines in recipients of allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2022.

Laurent V, Fronteau C, Antier C, Dupuis P, Tessoulin B, Gastinne T, Mahe B, Blin N, Dubruille V, Lok A, et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2020.